The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
China’s Foreign Ministry spokesperson, Mao Ning, Tuesday referenced unspecified “countermeasures” that might be used against countries now requiring COVID-19 testing from passengers travelling from China, according to the Associated Press. Due to a lack of information presented by China on the status of its COVID-19 outbreak, countries such as the United States, Australia, Canada, and others are requiring COVID-19 testing for passengers traveling from China prior to getting on a plane. These countries have fears around the emergence of novel variants and concerns over China’s sudden cessation of strict COVID-19 measures in December.
Monoclonal antibodies have proven to be expensive yet mighty for over 30 years, and now there is an opportunity to use these drugs against infectious diseases if finances and motivation align, reported The Washington Post. The COVID-19 pandemic demonstrated the usefulness of biologics for infectious disease treatment before a vaccine is available. While barriers such as high costs and the ever-changing nature of emerging disease variants are still present, scientists are researching candidates against malaria, Zika, or the hemorrhagic illness Lassa. They hope to create a small-dose, high-potency monoclonal treatment to assist with both reducing costs and easing administration burdens.
A recent Congressional investigation called into question the FDA’s approval of the Alzheimer disease drug (aducanumab) Aduhelm, as well as its manufacturer, Biogen, due to concerns about irregularities in the approval process and the extremely high cost of the drug, reported The New York Times. Biogen was found to have set aside a several billion-dollar marketing budget to tackle anticipated resistance on the value of the drug for the price upon its release. Approval of the drug in June 2021 was met with some health systems not offering it to patients because of its high price, dubious advantages, and risks of brain swelling and bleeding.
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Semaglutide Linked to Cardiovascular Gains, but Also Higher Health Spending
August 8th 2025A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.
Read More